Clinical trial · Observational
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
A Long-Term Follow-up Study for Subjects Previously Treated With A Century Therapeutics Cellular Therapy Product
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematological Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Solid Tumor Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cellular Therapy
- description
- Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.
- interventionNames
- Other: No Intervention
Primary outcomes (1)
- measure
- Number of Participants With any Adverse Events of Special Interest (AESI)
- timeFrame
- Up to 180 months
Secondary outcomes (3)
- measure
- Number of Participants With Cellular Product-related Serious Adverse Events (SAEs)
- timeFrame
- Up to 180 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures. * Participants received at least one treatment with a cellular therapy product in an eligible index trial. * Participant was withdrawn, early discontinued or completed an eligible index trial. * Participant is willing and able to comply with scheduled visits, study plan, and other study procedures. Exclusion Criteria: -This study has no exclusion criteria.
References
Publications (0)
Data not yet available